Plasma osteopontin as a predictor of coronary artery disease: Association with echocardiographic characteristics of atherosclerosis

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 3, 2010, Pages 201-206

  Abdel Azeez, Hala Abdel Hameed ^a   Al Zaky, Manar ^b  

^a Zagazig University   (Egypt)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Aortic valve sclerosis; Coronary artery disease; Coronary calcification; Mitral annular calcification; Osteopontin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; AORTA VALVE DISEASE; ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; PREDICTION; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANGINA PECTORIS; AORTIC VALVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCINOSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY STENOSIS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; OSTEOPONTIN; RISK FACTORS;

ANGINA;

EID: 77953501408     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20378     Document Type: Article

References (30)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.
3. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Circulation 1996;94:1175-1192.
4. Mody N, Tintut Y, Radcliff K, Demer LL. Vascular calcification and its relation to bone calcification: possible underlying mechanisms. J Nucl Cardiol 2003;10:177-183.
5. Schoenhagen P. Osteopontin, coronary calcification, and cardiovascular events: future diagnostic and therapeutic targets for disease prevention? Eur Heart J 2006;27:766-767.
6. MazzaliM, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. QJM 2002;95:3-13.
7. Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-807.
8. Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993;143:1003-1008.
9. Kwon HM, Hong BK, Kang TS, et al. Expression of osteopontin in calcified coronary atherosclerotic plaques. J Korean Med Sci 2000;15:485-493.
10. Khoury Z, Gottlieb S, Stern S, Keren A. Frequency and distribution of atherosclerotic plaques in the thoracic aorta as determined by transesophageal echocardiography in patients with coronary artery disease. Am J Cardiol 1997;79:23-27.
11. Atar S, Jeon DS, Luo H, Siegel RJ. Mitral annular calcification: a marker of severe coronary artery disease in patients under 65 years old. Heart 2003;89:161-164. (Pubitemid 36115097)
12. Jassal DS, Tam JW, Bhagirath KM, et al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin study. Eur Heart J 2008;29:1542-1547.
13. Friedewald WT, Levy RI, Fredrickson, DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. Ohmoria R, Momiyamaa Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333-337.
15. Coskun S, Atalar E, Ozturk E, et al. Plasma osteopontin levels are elevated in non-ST-segment elevation acute coronary syndromes. J Natl Med Assoc 2006;98:1746-1750.
16. Kato R, Momiyama Y, Ohmori R, et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 2009;73:152-157.
17. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993;13:120-125. (Pubitemid 23021592)
18. Rollo EE, Laskin DL, Denhardt DT. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol 1996;60:397-404. (Pubitemid 26325622)
19. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 1997;17:188-193.
20. Schmermund A, Erbel R. Unstable coronary plaque and its relation to coronary calcium. Circulation 2001;104:1682-1687. (Pubitemid 32947534)
21. Ishiyama M, Suzuki E, Katsuda J, et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009;85:189-196.
22. Chu H, Chen J, Guo R. The association between cardiac calcification and coronary artery disease. Acta Cardiol 2009;64:531-535.
23. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 1997;29:630-634.
24. Wong ND, Sciammarella M, Arad Y, et al. Relation of thoracic aortic and aortic valve calcium to coronary artery calcium and risk assessment. Am J Cardiol 2003;92:951-955.
25. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995;92:2163-2168.
26. Arnlov J, Evans JC, Benjamin EJ, et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study. Heart 2006;92:1514-1515.
27. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999;84:166-178. (Pubitemid 29070112)
28. Isoda K, Nishikawa K, Kamezawa Y, et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002;91:77-82.
29. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002;196:1047-1055.
30. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:1161-1170.